Jon C. Ogg - Author for 24/7 Wall St.
Lastest Stories by Jon C. Ogg
One group that probably has more insight into the housing market than the rest of us has just significantly upgraded its outlook for the housing market in 2020.
Published:
Citigroup released a note on Wednesday urging a bit more caution on Twitter, which has lost close to one-third of its value since September.
Published:
Wednesday's top analyst upgrades, downgrades and initiations included Activision Blizzard, Datadog, Delta Air Lines, Eli Lilly, FedEx, Halliburton, Kinder Morgan, Skechers, Teladoc and Waste...
Published:
The theme of environmental, social and governance (ESG) is a one that likely will not go away anytime soon. Now two more ETFs are launching to track the theme.
Published:
Here are five of the top gold-mining and gold-producing stocks that appear undervalued despite gold's performance in 2019.
Published:
Tuesday's top analyst upgrades, downgrades and initiations included Alcoa, Bed Bath & Beyond, Boeing, CenturyLink, DuPont, FedEx, Groupon, Johnson & Johnson, Micron Technology, Microsoft and...
Published:
Investors have a lot to consider as 2020 gets closer. 24/7 Wall St. has identified seven of the 30 Dow stocks to which value investors and others may flock.
Published:
Goldman Sachs believes that several health care companies can win, and it has three top picks for 2020 that may seem counterintuitive.
Published:
Credit Suisse has identified some of its favorite Outperform-rated stocks among the integrated and regulated utilities.
Published:
Monday's top analyst upgrades, downgrades and initiations included Adobe, Amgen, Bank of America, Broadcom, CME, Goldman Sachs, Micron Technology, PepsiCo, UnitedHealth, Urban Outfitters and Vertex...
Published:
One theme that investors love in good times and in bad is dividend investing. One strategy that has been around for years is known as the Dogs of the Dow.
Published:
One area of the financial markets that has grown like wildfire in the past two decades is the rise of exchange-traded funds. Merrill Lynch expects the market for ETFs and related products to rise to...
Published:
Independent research firm Argus sees better than 25% potential upside for Bristol-Myers Squibb in the coming year.
Published: